You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大藥廠(00950.HK)抗病毒藥物尤靖安成為疫情防治緊急戰略物資
格隆匯 02-03 17:46

格隆匯2月3日丨李氏大藥廠(00950.HK)公告,為做好新型冠狀病毒感染的疫情防控工作,2020年1月28日國家衞生健康委員會疾病預防控制局指導下、中國疾病預防控制中心編寫並在出版的最新《新型冠狀病毒感染的肺炎公眾防護指南》中,將干擾素列為新型冠狀病毒性肺炎防治藥物。此外,武漢、上海等地衞健委也先後將干擾素列為治療藥物。因此,該集團抗病毒藥物尤靖安®(重組人干擾素α2b凝膠)被安徽省經濟和信息化廳列入“安徽省應急藥品生產企業目錄”和“國家工業和信息化部重點物資保障信息監控平台”,成為本次疫情防治的緊急戰略物資之一。

尤靖安®為該集團自研產品,擁有獨家技術專利,於2001年在中國首創上市,開啟了外用干擾素市場新紀元,是唯一不需要冷藏、方便攜帶的產品。2019年10月,《重組人干擾素α2b凝膠治療高危人乳頭瘤病毒感染的藥物經濟學評價》發佈並刊登於《中國藥物經濟學》雜誌2019年第十四卷第十期,是國內首個通過抗HPV感染藥物經濟學研究的外用干擾素。尤靖安®用於治療病毒性皮膚病如尖鋭濕疣、帶狀皰疹、生殖器皰疹,以及宮頸HPV感染和宮頸柱狀上皮異位等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account